Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update
Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update
The Competitive Intelligence Report Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update“ provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) or its receptors (VEGF-R) for treatment of a variety of cancer indications and retinal diseases as of February 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Therapeutic antibodies targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGF-R) are a highly successful class of products as evidenced by total sales of US$ 15 bln in 2015. While Avastin has been known for years as a blockbuster biologic, anti-VEGF products Lucentis and Eylea for treatment of retinal diseases posted for the first time in 2015 higher sales than the anti-VEGF/R products for cancer treatment.
The commercial success of Avastin as a single product approved for many cancer indications and the forthcoming patent expiries in the major markets have attracted a number of biosimilar developments in advanced clinical stages.
Until now, less attention has been paid to anti-VEGF antibodies used for treatment of ophthalmic diseases although the approved antibody products are attractive targets for the second wave of biosimilar antibodies because of the impressive market growth fueled by the clinical success and patent expiries in the mid-term.
The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies or proteins for treatment of cancer and neo-angiogenic eye diseases. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The Competitive Intelligence Report Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update“ provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) or its receptors (VEGF-R) for treatment of a variety of cancer indications and retinal diseases as of February 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Therapeutic antibodies targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGF-R) are a highly successful class of products as evidenced by total sales of US$ 15 bln in 2015. While Avastin has been known for years as a blockbuster biologic, anti-VEGF products Lucentis and Eylea for treatment of retinal diseases posted for the first time in 2015 higher sales than the anti-VEGF/R products for cancer treatment.
The commercial success of Avastin as a single product approved for many cancer indications and the forthcoming patent expiries in the major markets have attracted a number of biosimilar developments in advanced clinical stages.
Until now, less attention has been paid to anti-VEGF antibodies used for treatment of ophthalmic diseases although the approved antibody products are attractive targets for the second wave of biosimilar antibodies because of the impressive market growth fueled by the clinical success and patent expiries in the mid-term.
The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies or proteins for treatment of cancer and neo-angiogenic eye diseases. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) Marketed Anti-VEGF/R Products in Oncology
5) Marketed Anti-VEGF Products in Ophthalmology
8) Lucentis Biosimilars in Ophthalmology
9) Eylea Biosimilars in Ophthalmology
10) Off-Label Use of Anti-VEGF in Ophthalmology
- Avastin, Zaltrap & Cyramza Sales 2008 – 2015
- Avastin Sales and Indication Portfolio
- Zaltrap Sales and Indication Portfolio
- Cyramza Sales and Indication Portfolio
- Anti-VEGF Biosuperior Pipeline in Oncology
- Bispecific Anti-VEGF Pipeline in Oncology
- Anti-VEGF-R Biosuperior Pipeline in Oncology
- Bispecific Anti-VEGF-R Pipeline in Oncology
5) Marketed Anti-VEGF Products in Ophthalmology
- Lucentis & Eylea Sales 2008 – 2015
- Lucentis Sales & Indication Portfolio
- Eylea Sales & Indication Portfolio
- Biosuperior Anti-VEGF in Ophthalmology
- Biosuperior Bispecific Anti-VEGF and Anti-VEGF Combinations in Ophthalmology
8) Lucentis Biosimilars in Ophthalmology
9) Eylea Biosimilars in Ophthalmology
10) Off-Label Use of Anti-VEGF in Ophthalmology
